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Abstract
Sphingosine-1-phosphate (S1P) activates a widely expressed family of G protein-coupled receptors, serves as a muscle
trophic factor and activates muscle stem cells called satellite cells (SCs) through unknown mechanisms. Here we show that
muscle injury induces dynamic changes in S1P signaling and metabolism in vivo. These changes include early and profound
induction of the gene encoding the S1P biosynthetic enzyme SphK1, followed by induction of the catabolic enzyme
sphingosine phosphate lyase (SPL) 3 days later. These changes correlate with a transient increase in circulating S1P levels
after muscle injury. We show a specific requirement for SphK1 to support efficient muscle regeneration and SC proliferation
and differentiation. Mdx mice, which serve as a model for muscular dystrophy (MD), were found to be S1P-deficient and
exhibited muscle SPL upregulation, suggesting that S1P catabolism is enhanced in dystrophic muscle. Pharmacological SPL
inhibition increased muscle S1P levels, improved mdx muscle regeneration and enhanced SC proliferation via S1P receptor 2
(S1PR2)-dependent inhibition of Rac1, thereby activating Signal Transducer and Activator of Transcription 3 (STAT3), a
central player in inflammatory signaling. STAT3 activation resulted in p21 and p27 downregulation in a S1PR2-dependent
fashion in myoblasts. Our findings suggest that S1P promotes SC progression through the cell cycle by repression of cell
cycle inhibitors via S1PR2/STAT3-dependent signaling and that SPL inhibition may provide a therapeutic strategy for MD.
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Introduction
Duchenne muscular dystrophy (DMD) is the most common
form of MD, a disease characterized by progressive loss of skeletal
muscle strength associated with pathological features including
muscle pseudohypertrophy, necrosis and regeneration, variation in
fiber size, and eventual muscle replacement by adipose tissue [1].
The disease affects cardiac and skeletal muscles including the
diaphragm, and patients usually succumb to the disease in their
twenties due to heart and respiratory failure. Mutations in the
dystrophin gene are responsible for DMD [2]. The dystrophin
protein physically interacts with the dystroglycan-associated
complex (DGC), which anchors the sarcolemma internally to the
cytoskeleton through dystrophin and externally to the extracellular
matrix (ECM), thereby facilitating the distribution of forces
generated upon muscle contraction. Disruption of the normal
bridge between ECM, DGC and cytoskeleton in patients with
DMD reduces membrane stability, resulting in myofiber injury
and necrosis [3].
Terminally differentiated skeletal muscle fibers harbor a
population of adult stem cells called SCs responsible for the
regenerative capacity of muscle [4]. SCs reside beneath the
myofiber basal lamina, juxtaposed to the sarcolemma, where they
exist in a quiescent state under resting conditions. Disruption of
the muscle architecture by traumatic injury or genetic instability
results in exposure of SCs to bioactive factors released from
injured muscle fiber and its niche, leading to their activation [5].
Activated SCs undergo a burst of proliferation and then migrate
from the muscle fiber periphery to sites of sarcolemmal injury. SCs
fuse with the injured muscle fiber, thereby generating multinucle-
ated myotubes and stimulating a myogenic program that closely
recapitulates development. SCs are fundamental to muscle
homeostasis, promoting muscle growth and repair of minor
injuries sustained during normal activity [6]. During the early
stages of DMD, SC activation and accompanying skeletal muscle
regeneration compensate for muscle fiber loss. However, the
chronic/degenerative phase of DMD is caused by a failure of
regeneration to keep up with ongoing injury and destruction of
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of SC reserves or their myogenic potential. Development of
methods that replenish the endogenous SC compartment, allow ex
vivo expansion of donor SCs for cellular therapy, or enhance the
myogenic potential of endogenous or donor SCs are each being
explored as therapeutic strategies in DMD [7].
S1P is a bioactive lipid that binds to a family of five G protein
coupled receptors [8]. Through activation of S1P receptors
(S1PRs) and their G protein partners, S1P modulates the activities
of adenylyl cyclase, the Ras/MAP kinase cascade, AKT signaling,
phospholipase C and small Rho GTPases, thereby affecting cell
survival, proliferation, migration and cell-cell interactions [9]. S1P
signaling is essential for many physiological processes including
angiogenesis, hematopoietic cell trafficking and development. S1P
is generated from sphingosine by a phosphorylation reaction
catalyzed by sphingosine kinases (SK), SphK1 and SphK2 [10].
Sphingosine can be regenerated from S1P through the actions of
specific and nonspecific lipid phosphatases. However, SPL is
responsible for irreversible S1P catabolism and has a major impact
on the availability of S1P signaling pools [11]. In addition to its
other activities, S1P signaling has been implicated in muscle
function, regeneration and the activation and proliferation of SCs
in culture [12–25]. Rodent muscles have been reported to express
three of the five known S1PRs [23]. Importantly, S1P was recently
identified as the signal that causes quiescent SCs to re-enter the
cell cycle, whereas chemical inhibition of S1P formation prevented
muscle regeneration [26]. This suggests a central role for S1P in
muscle homeostasis, consistent with our previous finding that
Drosophila mutants with dysregulated S1P metabolism exhibit a
myopathy [27]. However, the mechanism by which S1P activates
SCs is not known.
Signal Transducer and Activator of Transcription (STAT)
proteins represent a family of transcription factors that play a
central role in regulating inflammatory responses [28]. STATs
have been implicated in the control of cell proliferation, migration
and differentiation. STATs are recruited to cytokine and growth
factor receptor complexes upon their activation by ligand binding.
STATs then homodimerize or heterodimerize, translocate to the
nucleus and modulate transcription of target genes containing
consensus DNA-recognition motifs called gamma activated sites.
STAT proteins have been implicated in the regulation of muscle
physiology and SC functions [29,30]. DMD pathology has a
significant inflammatory component, and immunological events
are thought to play both reparative as well as injurious roles in the
disease process [31]. However, a direct role for STAT proteins in
the pathophysiology of DMD or other MDs has, to our
knowledge, not been reported.
In the present study, we observed dynamic changes in S1P
signaling after muscle injury. S1P deficiency due to disruption of
Sphk1 impaired muscle regeneration and SC recruitment to
injured fibers, as well as the proliferation and differentiation of SC-
derived myoblasts in vitro. In contrast, S1P accumulation due to
disruption of Sgpl1, which encodes SPL, enhanced SC-derived
myoblast functions. Mdx mice that serve as a model of MD
exhibited low circulating S1P levels consistent with evidence of
enhanced S1P catabolism. Administration of a nontoxic SPL
inhibitor blocked S1P degradation and improved mdx mouse SC
activation and muscle regeneration. Our results suggest that an
S1PR2/STAT3 signaling pathway leading to suppression of cell
cycle inhibitors is responsible for S1P-mediated SC activation.
Further, we show that SPL modulates SC functions in vitro, and
pharmacological SPL inhibition in vivo enhances the recruitment of
endogenous SCs into the cell cycle early in the muscle regenerative
process, thereby improving muscle regeneration in a mouse model
of MD.
Results
S1P synthesis, metabolism and signaling respond
dynamically to muscle injury
S1P signaling has been implicated in various aspects of muscle
biology [25]. However, the global effect of muscle injury on S1P
signaling and metabolism has not previously been characterized in
vivo. We previously performed temporal expression profiling on
whole muscle tissue in the mouse notexin (NTX) muscle
regeneration model in order to characterize myogenic genetic
reprogramming after injury [32]. A search of this microarray
database revealed that the expression levels of several genes
involved in S1P metabolism and receptor signaling change over
time after muscle injury (Figure 1A). The SPL gene (Sgpl1) was
significantly upregulated on day 3.5, concomitant with transcrip-
tional upregulation of the Myf5 transcription factor, the ECM
enzyme lysyl oxidase (Lox), the major SK Sphk1, and S1PR genes
s1pr2 and s1pr3. In contrast, s1pr1, s1pr4, s1pr5, and the gene
encoding S1P phosphatase 1 (Sgpp1) were downregulated or
unchanged at the time points interrogated in this array, and Sphk2
expression results were inconsistent using two different probes. To
confirm these findings, we first administered a single NTX
intramuscular (i.m.) injection into the gastrocnemius muscles of
C57BL/6 male mice (as described in Materials and Methods) and
evaluated SPL gene and protein expression at different time points
from day 0 (untreated) to day 10 after injury. Immunoblotting
confirmed that muscle SPL protein expression increased over
baseline levels by day 1 and reached maximal expression levels 5
days after injury (Figure 1B). To comprehensively characterize
genetic changes affecting S1P metabolism and signaling in the
aftermath of skeletal muscle injury, we administered a single NTX
injection into the gastrocnemius muscles of C57BL/6 male mice as
described above and followed the gene expression of S1PRs and
major genes of S1P metabolism over time from 6 hours to 20 days
in injured muscle by quantitative real time polymerase chain
reaction (qRT-PCR). Within 6 hours after injury, we observed a
100-fold induction of Sphk1, followed by upregulation of Sphk2,
Sgpl1 and Sgpp1 on days 3–5 or beyond after injury (Figure 1C).
Measurement of S1P in the plasma of C57BL/6 mice under
baseline conditions by liquid chromatography mass spectrometry
(LC-MS) revealed circulating S1P levels of approximately 2 mM,
consistent with our previous findings [33,34]. In response to focal
muscle injury, plasma S1P levels were found to increase by 50%,
(Figure 1D), a perturbation that is known to exert physiological
effects in other contexts [33–35]. We next characterized S1PR
expression at baseline and in injured muscle. The s1pr1 gene
expression levels in whole muscle exceeded those of the other four
S1PR subtypes at rest and after injury (Figure 1E). From 6 hours
through day 3, s1pr1 expression increased 5-fold and decreased
thereafter, diminishing to near baseline levels by day 5. In
contrast, a 25-fold increase in s1pr2 expression was observed by
day 3 and remained high through day 5 (Figure 1F). The
expression levels of genes encoding S1PR3-5 also increased over
time but remained low compared to those encoding S1PR1 and
S1PR2 (Figures 1E and F). These findings establish that dynamic
changes in S1P metabolism and signaling occur in the skeletal
muscle fiber and microenvironment in response to injury.
SphK1 is required for maximal muscle repair
Use of nonspecific SK inhibitors has implicated a role for S1P in
muscle regeneration [23]. We wished to confirm this finding using
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plays a specific role in muscle regeneration, as implicated by the
profound Sphk1 upregulation observed in injured muscle. Toward
that end, we compared S1P levels and muscle regeneration
capacity in WT mice versus SphK1 KO mice that lack the major
enzyme required for S1P biosynthesis, but which are viable and
healthy by virtue of an intact Sphk2 gene [36]. S1P levels in SphK1
KO plasma were consistently between 40% to 57% of the
circulating S1P levels observed in WT plasma at day 0 and
through day 5 post-injury (Figure 2A). Muscle regeneration was
compared in WT and SphK1 KO mice by examining the
appearance of Hematoxylin & Eosin (H&E)-stained frozen sections
and by quantification of nucleated, regenerating muscle fibers
found at the point of maximal injury determined by serial
sectioning and examination of the entire muscle, as described in
Materials and Methods. As shown in Figure 2B, on day 5 after
NTX injury both WT and SphK1 KO muscles contained fibers
with centralized nuclei, indicating the presence of muscle
regeneration at the point of maximal injury. At that time, there
was no discernable difference between WT and SphK1 KO
muscle fibers. However, by day 10 after injury, a compact
assembly of centrally nucleated regenerating fibers was observed at
the point of maximal injury in the WT muscles. In contrast, the
regenerating fibers in the SphK1 KO muscles at day 10 appeared
more sparsely organized, and quantification of regenerating fiber
number/mm
2 revealed a statistically significant reduction in
regenerating fiber numbers in SphK1 KO muscles compared to
WT muscles (Figures 2B and C).
SphK1 KO mice exhibit reduced SC activation and
proliferation
To investigate whether inefficient muscle regeneration in
SphK1 KO mice was associated with poor SC proliferation,
resident SCs in tibialis anterior sections of WT and SphK1 KO
mice isolated at rest and 10 days after injury were co-stained with
Figure 1. Dynamic changes in S1P signaling after muscle injury. A) Heat map of S1P receptors, S1P metabolic genes and other markers in WT
C57BL/6 mouse skeletal muscle from day 0–40 after NTX injection. Red is induced, green is repressed relative to the mean. Note: two probes were
available for some genes. Lox=lysyl oxidase; S1pr1–5=S1PRs; Sgpl1=SPL. Sgpp=S1P phosphatases; Sphk=sphingosine kinases. B) SPL protein
(Sgpl1p) expression is induced after muscle injury, as determined by immunoblotting (above) and imageJ quantification relative to day 0 (uninjured
muscle) and normalized to actin (below). C) Relative gene expression of Sphk1, Sphk2, Sgpl1 and Sgpp1 (normalized to Gapdh) were evaluated in
whole muscle over time after injury by qRT-PCR. Gene levels are depicted relative to their own baseline levels (day 0 set as 1 for all genes). D)
Corresponding plasma S1P levels were measured by LC-MS, E) Relative gene expression of S1PRs was determined as in ‘‘C’’ and is depicted relative to
S1pr1 (day 0 set as 1 for S1pr1 only). F) S1PR induction is shown relative to baseline levels for each receptor (day 0 set as 1 for all genes). * indicates
significant difference compared to day 0, p#0.05. Data are means 6 SD; n=3–5/group.
doi:10.1371/journal.pone.0037218.g001
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cadherin, along with laminin to identify basal lamina and Hoechst
staining of nuclei. SCs were identified as Pax-7 or M-cadherin
positive, sub-laminar, mono-nucleated cells found in association
with myofibers. A representative SC is shown in Figure 2D.
Although SphK1 KO muscles appeared to harbor fewer SCs on
day 0 compared to WT, the differences were not statistically
significant. In contrast, 10 day post-injury SphK1 KO muscles
harbored significantly fewer SCs than injured WT muscles, as
determined by Pax-7 or M-cadherin staining (Figure 2E). Using
qRT-PCR to measure the relative gene expression levels of SC
markers c-Met, M-cadherin and Pax-7, we confirmed that SC
markers were reduced in SphK1 KO muscles after injury
(Figure 2F). Our results indicate that SphK1 is involved in
mediating effective muscle regeneration and SC activation after
injury.
S1P metabolism influences primary SC responses in vitro.
Considering the importance of SphK1 in muscle regeneration
and SC recruitment, we next examined the role of SphK1 in
mediating SC functions in response to injury using a cell culture
system. We wished to examine the intrinsic role of SphK1 in
mediating SC functions in autocrine fashion, as well as the
Figure 2. SphK1 disruption and S1P deficiency impairs muscle regeneration and SC recruitment. NTX injury was performed in WT
C57BL/6 mice and SphK1 KO mice in the C57BL/6 background. Blood plasma and gastrocnemius muscles were harvested at different time points after
injury. A) Plasma levels of WT and KO mice. B) Representative H&E stained frozen muscle sections of WT and SphK1 KO mouse muscles at the point of
maximal injury. Scale bar=50 microns. C) Fiber counts at days 5 and 10. D) Representative immunofluorescence staining on injured C57 BL/6 muscle
sections with Hoechst (blue) for nucleus, laminin (red) for basal lamina and Pax-7 (green) or M-cadherin (green) for SCs. Arrow shows merged signals.
E) Quantitation of SCs, identified by sublaminar mononucleated cells expressing Pax-7 or M-cadherin in WT and SphK1 KO muscles at baseline (day 0)
and 10 days after injury. * p#0.05 (KO at day 10 compared to WT at day 10 for both markers). F) Gene expression of SC markers (Pax-7, M-cadherin
and c-Met) in uninjured (D0) and injured muscles at 5 and 10 days post injury. Data are expressed as means 6 SD; n=4 for immunostained
cryosections; n=3 for Western blot analysis; n=3–5 for qRT-PCR; * indicates a significant difference between WT and KO at that time point, p#0.05.
doi:10.1371/journal.pone.0037218.g002
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functions by influencing the muscle microenvironment. Toward
that end, we isolated activated SCs from injured SphK1 KO and
WT mice, cultured them in SphK1 WT or KO serum, and
measured their ability to proliferate and differentiate. The
combination of SphK1 KO cells and KO serum resulted in
reduced proliferation compared to controls, as determined by
BrdU uptake by desmin-positive cells (Figures 3A and B). A
global (non-autonomous) requirement for SphK1 in mediating
activated SC proliferation was identified, as shown by reduced
proliferation of WT SCs in KO serum, whereas KO SC
proliferation was increased in the presence of WT serum.
Activated SCs also appear to have an intrinsic requirement for
SphK1 to promote maximal proliferation, as WT serum did not
restore KO SC proliferation to WT levels. Similar studies
established that SCs also require SphK1 in non-autonomous
fashion to support myotube formation, as determined by eMHC-
positive myotubes after 48 hours in differentiation media
(Figures 3C and D). SPL plays a major role in regulating S1P
levels in cells and tissues. Mice homozygous for a gene-trap KO
Sgpl1 allele are unable to survive the neonatal period. In contrast,
mice heterozygous for this allele exhibit a 30–40% increase in
circulating S1P levels over WT levels and live normal lifespans
[33]. In contrast to SCs derived from SphK1 KO mice, SCs
isolated from SPL heterozygous null mice showed more robust
proliferation (Figures 3E and F) and differentiation responses
(Figures 3G and H) than littermate WT control SCs when
incubated in the presence of their own serum. These studies
establish that both biosynthetic and catabolic enzymes involved in
S1P metabolism play an important role in the regulation of
primary SC proliferation and differentiation.
Mdx mice exist in a state of S1P-deficiency
In consideration of our finding that S1P signaling is induced
after muscle injury, we suspected that S1P signaling might also be
altered in dystrophic muscles. To examine this possibility, we
evaluated the levels of S1P and S1P-related gene expression in the
dystrophic muscles of mdx mice, which harbor a point mutation in
the murine dystrophin gene and are a rodent model for human
DMD, in comparison to C57BL/10J control muscles [37]. Under
basal conditions, eMHC mRNA was elevated in dystrophic
muscles of mdx mice compared to control muscles, reflecting a
state of continual degeneration/regeneration characteristic of
dystrophic muscle (Figure 4A). No differences were observed
between the two lines in gene expression levels of Sphk1 and Sphk2,
which suggests that S1P biosynthesis is not likely to be impaired in
mdx mice (Figures 4B and C). In contrast, the gene expression
of S1P catabolic enzymes Sgpp1 and Sgpl1 were elevated
compared to control muscles (Figures 4D and E). Consistent with
this finding, SPL protein levels were elevated in mdx muscles
compared to control muscles (Figure 4F). Importantly, circulating
S1P levels of mdx mice were significantly lower than resting WT
control plasma (Figure 4G). In fact, mdx S1P levels were similar
to levels observed in SphK1 KO mice. These important findings
reveal that dystrophic mdx mice exist in a state of S1P deficiency
that is comparable to the S1P-deficient state of SphK1 KO mice
and, thus, could have an impact on SC functions and muscle
Figure 3. Function of SCs isolated from sphingolipid mutant mice. A) Proliferation of WT and SphK1 KO primary SCs isolated 3 days after NTX
injury, measured by BrdU uptake of desmin-positive cells incubated with either SphK1 WT or KO serum. B) Representative immunofluorescence
images for experiment in ‘‘A’’. Desmin-stained cells, green; BrdU-stained nuclei, orange. C) Differentiation of SC-derived myoblasts as shown by
myotube formation. D) Representative immunofluorescence images for experiment in ‘‘C’’. Hoechst-stained nuclei, blue; eMHC-stained fibers, green.
E) Proliferation of SPL heterozygous null (+/2) and littermate control (+/+) mouse primary SC isolated 3 days after injury. F) Representative images for
experiment in ‘‘E’’. Desmin-stained cells, green; BrdU-stained nuclei, orange. G) Differentiation of heterozygous null (+/2) and littermate control (+/+)
mouse SC. H) Representative immunofluorescence images for experiment in ‘‘G’’. Hoechst-stained nuclei, blue; eMHC-stained fibers, green. * indicates
p#0.05.
doi:10.1371/journal.pone.0037218.g003
S1P Facilitates Muscle Repair through S1PR2/STAT3
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37218regeneration. However, unlike SphK1 KO mice, the mdx S1P
deficiency appears to be due to enhanced S1P catabolism, rather
than impaired biosynthesis.
Inhibition of SPL in vivo enhances SC activation in mdx
mice
We hypothesized that, like WT muscles injured with NTX,
dystrophic muscles may also upregulate SPL in response to muscle
injury. However, in the case of mdx mice, the injury results from
intrinsic muscle fiber instability. We further hypothesized that the
resulting chronically S1P-deficient state of dystrophic mice
contributes to MD pathology by preventing efficient muscle
repair. To address whether transient SPL inhibition could enhance
muscle regeneration in mdx mice, we employed 2-acetyl-5-
tetrahydroxybutylimidazole (THI), a nontoxic FDA-approved
component of caramel food coloring that functions as an SPL
inhibitor in vivo [38]. We have shown previously that THI
treatment suppresses SPL activity and raises circulating plasma
S1P levels by approximately 25–30% [33]. To assess the effect of
SPL inhibition on muscle S1P levels, THI was administered in
water for either 2 or 5 days to WT mice after NTX injury, and
gastrocnemius muscle S1P levels were measured on day 5 post
injury by LC-MS. THI treatment raised muscle S1P levels by 3–5-
fold (Figure 5A). Mdx mice then received NTX injections in
combination with orally administered THI or vehicle for 5 days
after injury. Areas of uninjured mdx muscles showed the expected
pathological findings including heterogeneous fiber size, the
presence of large, necrotic fibers, small centrally nucleated fibers,
and extensive inflammatory cellular infiltrates (Figure 5B). Five
days after NTX injury, mdx muscles showed many areas lacking
regenerating fibers at the point of maximal injury. In contrast,
muscles from THI-treated mdx mice exhibited regenerating
muscle architecture indistinguishable from regenerating WT
muscle. THI-treated mdx muscles contained 2-fold more regen-
erating fibers than vehicle-treated mdx controls (Figure 5C).
Quantification of SC numbers in regenerating mdx muscle using
either M-cadherin or Pax-7 immunostaining and fluorescence
microscopy demonstrated improvement in SC activation within
the muscle fibers of THI-treated mdx mice compared to control
mdx mice (Figure 5D). Flow cytometry approaches represent an
unbiased method to identify SCs based on the presence or absence
of specific cell surface markers. This approach was employed to
confirm the effect of THI on SC proliferation that we had
observed using histological methods as described above. Toward
that end, CD45-negative, CD31-negative, Sca1-negative, alpha-
integrin7-positive, CD34-positive SCs were quantified using flow
cytometry of disaggregated muscle cells as described [39]. As
shown in Figure 5E, THI treatment was associated with a
significant increase in the number of SCs present in injured mdx
muscle. These findings demonstrate that SPL inhibition enhances
muscle regeneration and SC proliferation in a rodent model of
MD.
S1P recruits SCs through activation of S1PR2 and STAT3
S1P signaling has been implicated in SC activation [20,26,40].
Importantly, however, the molecular mechanism responsible for
the contribution of S1P signaling to SC activation has not been
determined. The STAT3 transcription factor promotes cell
proliferation, survival and differentiation, has been implicated in
mediating SC functions, and has been linked to S1P receptor
signaling in cancer [28,30,41–46]. Therefore, we investigated the
potential impact of THI treatment on STAT3 status in mdx
muscles. STAT3 activation as shown by its phosphorylation on
residue T705 was higher in injured muscles of THI-treated mdx
mice compared to vehicle-treated mdx controls on day 5 post-
injury (Figure 6A). To determine the S1PR requirements for
STAT3 activation, we evaluated STAT3 phosphorylation in the
presence and absence of S1PR antagonists in vitro. STAT3
phosphorylation was significantly reduced in SC-derived primary
myoblasts treated with the S1PR2 antagonist JTE-013, whereas
the S1PR1 antagonist W123 and the S1PR3 antagonist BML-241
had no impact on STAT3 phosphorylation (Figure 6B). STAT3
has been reported to negatively regulate cell cycle inhibitor
proteins p21 and p27, thereby inducing cell cycle progression [41].
Importantly, SC-derived myoblasts treated with the S1PR2
antagonist JTE-013 showed a reduction in STAT3 phosphoryla-
Figure 4. Dystrophic mice are characterized by an S1P-deficient state. Gene expression of eMHC, a marker of regenerating muscle, and key
enzymes involved in S1P metabolism were examined by qRT-PCR in C57BL10/J and mdx (C57BL/10J background) mouse muscles under basal
conditions. Data are means 6 SD, n=5/group; * indicates P,0.05. A) eMHC (Myh3) gene expression. B) Sphk1 gene expression. C) Sphk2 gene
expression. D) Sgpp1 gene expression. E) Sgpl1 gene expression. F) SPL protein expression. G) Plasma S1P levels. Data are means 6 SD, n=4–5/group
for plasma S1P; * indicates p#0.05. Gene expression levels for qRT-PCR were normalized to GAPDH.
doi:10.1371/journal.pone.0037218.g004
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(Figure 6C). To further confirm these findings, we employed
siRNA to knockdown the expression of S1PR2 and then evaluated
the impact on STAT3 activation. As shown in Figure 6D, SC-
derived myoblasts transfected with S1PR2 siRNA exhibited a 75%
reduction in S1PR2 mRNA expression. S1PR2 knockdown
resulted in a marked reduction in STAT3 phosphorylation,
similar to the results obtained with JTE-013 (Figure 6E). Given
these findings, we analyzed the effects of JTE-013 in vivo 5 days
after NTX injury. We found that there was a significant decrease
in centrally nucleated myofibers/mm
2 after treatment with JTE-
013 (Figures 6F and G). Further, JTE-013 treatment was
associated with a significant decrease in the number of SCs when
evaluated by FACS analysis (Figure 6H). These findings
demonstrate that S1PR2 activation and downstream activation
of STAT3 are essential for efficient muscle regeneration and SC
proliferation.
Figure 5. SPL inhibition improves muscle regeneration and SC recruitment in MD. A) Treatment of WT mice with THI for 2 days (2D) or 5
days (5D) results in elevated muscle S1P levels compared to vehicle-treated controls at 5 days post injury (5DPI); * indicates p#0.05. Data are means
6 SD, n=4–5/group. B) Mdx mice received NTX+THI or vehicle daily on days 21 to 5. On day 5, mice were euthanized and gastrocnemius muscles
were harvested. Ten mm tissue cryosections were obtained every 200 mm in sets of 4. H&E stained sections were examined for point of maximal injury.
Representative photographs are shown. Scale bar=50 microns. Recovering WT control and resting mdx muscles are shown for comparison. C) Fiber
quantification of experiment in ‘‘B’’. Centrally nucleated myofibers were counted in a field containing only regenerating fibers and normalized to
1m m
2 area. * p#0.05. D) Quantification of SC in situ in mdx mouse muscles identified by M-cadherin or Pax-7 expression and localization beneath
the basal lamina. * indicates p#0.05. E) Flow cytometry analysis of freshly isolated muscle cells from mdx mice treated with THI or vehicle at 5 days
post injury. SCs were identified as CD45-, CD31-, Sca1-, integrin alpha-7+ and CD34+ cells; * indicates p#0.05, data are means 6 SD, n = 5/group.
doi:10.1371/journal.pone.0037218.g005
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such as pericytes, endothelial cells and mesoangioblasts have been
implicated in muscle regeneration and contribution to the SC
niche [47–49]. To investigate the potential impact of S1P/S1PR2
signaling on STAT3 activation in these cell types, we applied
exogenous S1P to representative lines of each, including human
umbilical vein endothelial cells (HUVECs), the pericyte cell line
C3H10T1/2 and the M25.2 clonally-derived populations of
Figure 6. STAT3 and S1PR2 signaling interactions in muscle regeneration of WT and mdx mice. A) Mdx mice received NTX with or
without THI treatment. Muscles were harvested on day 5 post-injury, and whole muscle extracts were examined for total STAT3 (STAT3-T) and
phosphorylated STAT3 (STAT3-P) protein levels. Actin is used as a loading control. B) STAT3 activation in SC-derived myoblasts treated in vitro with
10 mM S1PR1 (R1i), S1PR2 (R2i), and S1PR3 (R3i) antagonists. S1PR1 is used as a loading control, as its expression is invariant under these conditions.
C) WT SC-derived primary myoblasts were treated with S1PR2 antagonist (JTE-013) or vehicle, and whole cell extracts were examined for STAT3
phosphorylation, total STAT3 and p21 and p27 protein levels. Actin is used as a loading control. D) SC-derived primary myoblasts were treated with
either 50 nM siRNA against S1PR2 or mock transfection. S1PR2 knockdown was confirmed by qRT-PCR. E) Whole cell extracts of control and S1PR2
knockdown cells were examined for phosphorylated STAT3 and actin protein levels by immunoblotting. p=0.03 (siRNA vs. mock) for relative
densitometric levels of STAT3-P/actin from two experiments performed in duplicates. F) WT mice were treated with NTX plus antagonist of S1PR2
(JTE-013) or vehicle by subcutaneous injection. Muscles were harvested 5 days post injury; regenerating fibers were imaged, and G) regenerating
fibers were quantified. H) Flow cytometry analysis of SCs from WT mice treated with JTE-013 or vehicle at 5 days post injury; * indicates p#0.05, data
are means 6 SD, n=5/group.
doi:10.1371/journal.pone.0037218.g006
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37218mesoangioblasts [50]. As shown in Figure S1, treatment of SC-
derived myoblasts with 1 mM exogenous S1P resulted in robust
activation of STAT3, which was prevented by pretreatment with
10 mM JTE-103. In contrast, HUVECs and M25.2 cells exhibited
minimal STAT3 phosphorylation in response to S1P, and STAT3
phosphorylation was undetectable in C3H10T1/2 cells under the
conditions we employed. However, high STAT3 activation was
observed when C3H10T1/2 cells were treated with recombinant
mouse Il-6 (data not shown).
S1P activation of STAT3 is mediated via an S1PR2/Rho-
GTPase-mediated pathway
We next sought to define the link between S1PR2 signaling and
STAT3 activation. STAT3 activation is mediated by the ligation
of various cytokines to gp130 and its associated receptors, which
are then activated by JAK kinases, forming a docking site for
STAT3 [28]. STAT signaling pathways are responsive to many
intrinsic and environmental stimuli, including MAP kinases and
Rho GTPases, known downstream targets of S1PR signaling [51–
53]. We observed no effect of MAP kinase inhibitors on STAT3
phosphorylation in SC-derived primary myoblasts (data not
shown). The Rho GTPase Rac1 has been shown to induce
STAT3 activation in response to growth factors [54]. Surprisingly,
SC-derived primary myoblasts treated with Rac1 inhibitors
exhibited dose-dependent and significant STAT3 activation in
comparison to vehicle-treated controls (Figure 7A). In contrast,
RhoA inhibitors reduced myoblast STAT3 activation (Figure 7B).
Importantly, when myoblasts were treated with an S1PR2
antagonist, Rac1 activation was enhanced, concomitant with
STAT3 inactivation, as shown by reduced cellular levels of
phosphorylated STAT3 (Figure 7C). Myoblasts were found to
contain abundant Rac1 and low levels of RhoA and Cdc42 (data
not shown). Therefore, to confirm the influence of Rac1 and
RhoA on myoblast STAT3 activation, myoblasts were transfected
with either a dominant negative construct of Rac1, a wild type
RhoA construct or a GFP vector control, followed by measure-
ment of Rac1, RhoA, total and phosphorylated STAT3 protein
levels, with GAPDH serving as a loading control. As shown in
Figure 7D, the expression in myoblasts of either dominant
negative Rac1 or wild type RhoA resulted in higher activation of
STAT3 in comparison to GFP control-transfected cells. These
cumulative results indicate that in myoblasts, as in other cell types,
S1P signaling through S1PR2 negatively regulates Rac1. Howev-
er, in contrast to other cell types, inhibition of myoblast Rac1
releases STAT3 from suppression, thereby allowing it to repress
cell cycle inhibitors and recruit SCs into the cell cycle.
STAT3 activation is required to enhance muscle
regeneration and SC functions through SPL inhibition in
mdx mice
Importantly, treatment with the STAT3 signaling pathway
inhibitor WP1066 reversed the positive effects of THI on mdx
muscle recovery as well as SC proliferation after injury,
demonstrating that THI potentiates SC proliferation through a
STAT3-mediated pathway (Figures 7E–G). Our findings dem-
onstrate a mechanistic link between S1P metabolism and S1PR2-
dependent STAT3 signaling and suggest that this link is critical for
THI-mediated improvement in muscle regeneration.
Discussion
In this study, we have explored the function of the S1P signaling
pathway within the context of muscle injury using the well-
characterized NTX injury model. Initial exploratory studies
characterized the impact of muscle injury on S1P signaling in
WT murine muscle. Our findings demonstrate that, subsequent to
acute muscle injury, dynamic changes occur in the expression of
S1P biosynthetic and catabolic enzymes in whole muscle tissue.
Marked Sphk1 induction was observed, followed by elevation of
plasma S1P levels. Importantly, circulating S1P level elevations of
the magnitude observed in our study have been implicated in
mediating physiologically relevant effects such as radioprotection
and ischemic cardioprotection [33–35]. Plasma S1P gradually
returned to baseline levels concomitant with upregulation of SPL,
the enzyme responsible for irreversible S1P degradation and the
major regulator of S1P levels in cells and tissues. S1PR expression
also changed over time after muscle injury, with S1PR1 and
S1PR2 expression exhibiting the most significant changes.
To establish the physiological relevance of Sphk1 induction
after muscle injury, we tested the efficiency of muscle regeneration
in SphK1 KO mice. Our studies in this model demonstrate a
specific requirement for SphK1 in both muscle regeneration and
endogenous SC recruitment. Consistent with these findings,
myoblast-derived SCs isolated from SphK1 KO mice exhibited
a reduced capacity to proliferate and differentiate in vitro. Further,
the S1P-deficient serum from SphK1 KO mice did not sustain
optimal proliferation and differentiation of WT myoblast-derived
SCs. These findings suggest that SphK1-derived S1P likely acts
through a combination of autocrine mechanisms and effects on the
muscle niche to promote SC functions and thereby facilitate
regeneration after muscle injury.
We observed that SPL gene and protein expression rise after
injury in WT mice and are also elevated under baseline conditions
in the dystrophic muscles characteristic of mdx mice. Our results
corroborate a previous study that found Sgpl1 upregulation as a
component of a ‘‘chronic inflammatory response’’ pattern in mdx
mice [55]. SPL is upregulated under a variety of stressful
conditions including ischemia, infection, injury and DNA damage
[56]. In contrast, the expression of enzymes required for S1P
biosynthesis were not found to be elevated in mdx muscles. We
propose that chronic muscle injury in MD may induce genetic
changes that favor S1P catabolism and result in S1P deficiency,
thereby impairing SC activation and muscle regeneration. The
effect of chronic S1P depletion in dystrophic muscles, SCs and/or
the muscle niche could in part explain the failure of genetic and
cellular therapies to restore muscle health in MD.
Our findings in the mdx mouse model suggested the possibility
that SPL inhibition could serve as a strategy to boost S1P levels,
enhance endogenous SC functions and thereby promote muscle
regeneration in MD. This notion is supported by our finding that
myoblast-derived SCs isolated from SPL KO mice have greater
capacity to proliferate and differentiate in vitro than SCs isolated
from littermate controls. Genetic or pharmacological SPL
suppression protects against other forms of injury including
ischemia, DNA damage, and autoimmune and infection/inflam-
matory insults [33,34,57,58]. Our results in mdx mice demonstrate
that regeneration after injury of dystrophic muscles is improved by
pharmacological SPL inhibition using the nontoxic food additive,
THI. SPL inhibition by THI results in an expansion of
endogenous SC pools, as determined by SC quantification using
histological methods and analysis by flow cytometry. We speculate
that the expansion of SCs with THI treatment results in a larger
reserve population of SCs capable of activating with subsequent
injury. It remains to be tested whether SPL inhibition using THI
or other SPL inhibitors in recipients of cellular therapy will
facilitate donor SC proliferation and incorporation into dystrophic
muscles.
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37218Figure 7. S1P activation of STAT3 is mediated via an S1PR2/RhoGTPase pathway. SC-derived myoblasts were treated with indicated dose
of: A) Rac1 inhibitor, or B) RhoA inhibitor for 24 hours in complete media, and cell lysates were immunoblotted with indicated antibodies. Levels of
total STAT3 (STAT3-T) and phosphorylated STAT3 (STAT3-P) were measured and compared to actin loading control. C) SC-derived myoblasts were
treated with 10 mM S1PR2 antagonist JTE-013 (R2i) for 20 hours, cells were incubated in fresh media for 5 minutes with or without R2i, and activated
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37218We have shown that STAT3 activation plays a critical role in
mediating the positive effects of SPL-inhibition on muscle
regeneration. This conclusion is supported by our findings that
the muscles of THI-treated mdx mice exhibit enhanced STAT3
activation, whereas the increases in regenerating fiber numbers
and SC recruitment after injury associated with THI treatment are
attenuated by inhibition of STAT3-dependent signaling. Several
reports have linked S1P signaling to the regulation of STAT3,
including the recent study establishing that paracrine S1P
signaling events are responsible for constitutive STAT3 signaling
in cancer [46]. In addition, S1P and S1P-containing HDL activate
STAT3 signaling in ventricular cardiomyocytes and in prostate
cancer cells [59,60]. While interleukin-6 and STAT3 are known to
participate in muscle biology and SC functions [29,30], the only
published report we are aware of that links STAT3 to MD was an
exploratory survey of transcription factors in mdx [61]. Whether
other STAT3 activators could be useful in MD remains to be
tested. It is interesting to note that the STAT3 activator LIF
enhances muscle regeneration through the incorporation of
transplanted donor myoblasts into injured and diseased muscle
fibers [42,62–64].
Our results have implicated a critical role for S1PR2 signaling
in mediating SC recruitment and muscle regeneration. This
notion is supported by our finding of reduced numbers of
regenerating fibers and endogenous SCs in response to muscle
injury in mice pretreated with the S1PR2 antagonist JTE-013.
This effect occurs at least in part at the level of the myoblast, since
activated STAT3 is markedly reduced in myoblasts treated with
S1PR2 siRNA or with the S1PR2 inhibitor JTE-013 but not with
other receptor inhibitors. Importantly, STAT3 has been shown to
repress cell cycle inhibitor proteins including p21 and p27, which
has been proposed as one of the major mechanisms responsible for
STAT3’s ability to promote cell proliferation [41]. We found that
S1PR2 inhibition by JTE-013 in myoblasts reduces STAT3
activation and results in marked upregulation of p21 and p27. Our
cumulative findings suggest that the activation of SCs by S1P may
be mediated through a pathway involving activation of S1PR2 and
STAT3, leading to the repression of cell cycle inhibitors and de-
repression of the quiescent state.
Our results suggest that S1PR2 signaling activates STAT3
through a process that involves its reciprocal effects on small Rho
GTPases. Specifically, we find that inhibition of S1PR2 in
myoblasts correlates with Rac1 activation concomitant with
STAT3 inhibition, whereas Rac1 inhibition or RhoA overexpres-
sion in myoblasts leads to activation of STAT3. The finding that
S1PR2 activation leads to inhibition of Rac1 in myoblasts is
consistent with the known functions of S1PR2 in other cell types
[65,66]. In contrast to the effect of S1PR2 on Rac1, RhoA has
been shown to be activated by S1PR2 signaling [67,68]. There is
considerable evidence that wild type and mutant Rac1 and other
Rho small GTPases can activate STAT3, especially within the
context of cancer [53]. However, our findings suggest that in
myoblasts inhibition of Rac1 and activation of RhoA by S1PR2
contribute to activation of STAT3.
STAT3 plays a role in rodent and human SC proliferation,
migration and differentiation [30,42–44,69]. Therefore, we
consider it likely that S1P signaling plays a critical role in multiple
SC functions through its impact on STAT3 signaling. However, in
our investigation of primary SCs from WT and sphingolipid
mutant mice, it was not possible to segregate proliferation from
differentiation effects, since a change in proliferation rate would
reduce the number of SCs available to undergo fusion, nuclear
accretion, and myotube formation. Therefore, additional studies
will be required to specifically delineate the involvement of S1P/
S1PR2/STAT3 signaling in SC differentiation and migration.
In summary, we have found that S1P signaling changes
dynamically in response to muscle injury, plays a role in SC
activation and muscle regeneration through an S1PR2/STAT3-
dependent signaling pathway, and that SPL can be targeted to
enhance muscle regeneration in a model of MD. Many of the
known functions of S1P, including its role in angiogenesis, nitric
oxide metabolism, innate and adaptive immunity, calcium
homeostasis and cytokine and growth factor signaling, are
important components of the physiological response to muscle
injury. It will be important to determine how S1P-dependent
signaling and SPL inhibitory strategies impact the many facets of
muscle regeneration. Considering the recently described role of
S1P as a histone deacetylase inhibitor, it is also possible that S1P
influences epigenetic reprogramming in regenerating muscle [70].
The ubiquitous role of S1P signaling in physiology raises the
concern that targeting SPL may be too toxic for practical use.
However, humanized SPL mice exhibiting 10–20% of WT SPL
activity levels live a normal lifespan, are healthy, reproductive and
exhibit lymphopenia as their only phenotype [71]. Human clinical
trials using small molecule inhibitors of SPL appear promising for
the treatment of autoimmune diseases [58,72]. These findings
suggest that brief, intermittent or incomplete pharmacological SPL
suppression is a feasible therapeutic strategy for enhancing SC
functions in MD and other diseases of skeletal muscle. Future
studies employing other murine models and large animal models
of MD should help to clarify this issue.
Materials and Methods
Reagents
Antibodies to BrdU [BU1/75 (ICR1)], M-cadherin, SphK1 and
S1PR1 were purchased from Abcam (Cambridge, MA, USA).
Developmental eMHC antibody (clone RNMy2/9D2) was from
Vector Laboratories (Burlingame, CA, USA). Antibodies to
desmin (clone DE-U-10), laminin and actin were from Sigma-
Aldrich (St. Louis, MO, USA). Hoechst nuclear stain was from
VWR scientific (Radnor, PA, USA). Pax7 antibody was from
Developmental Studies Hybridoma Bank (Iowa City, IA, USA).
Antibody to murine SPL was generated as we described previously
[73]. Antibodies to p21, p27 and GAPDH were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies to total
and phosphorylated STAT3 were from Cell Signaling Technology
(Danvers, MA, USA). Antibody to Rac1 was from BD Transduc-
tion Laboratories (San Jose, CA, USA). Fluorophore-conjugated
secondary antibodies (Alexa Fluor) were obtained from Molecular
Probes (Eugene, OR, USA). Fluorophore-conjugated antibodies
anti-CD31 PE-Cy7, anti-CD34 efluor 450, anti-CD45 FITC, anti-
Sca-1 PerCP Cy5-5 were from eBioscience (San Diego, CA, USA).
Rac1 was pulled down with GST-PAK1 fusion protein and immunoblotted with Rac1 antibody. STAT3 activation (STAT3-P) also shown for this
experiment. D) Myoblasts were transfected with GFP, dominant negative Rac1 (Rac1 DN) or wild type RhoA (RhoA WT) plasmid constructs. Forty-eight
hours later, cell lysates were immunoblotted to detect total and phosphorylated STAT3, GFP, Rac1 and RhoA, with GAPDH used as a loading control.
E) Representative micrographs (106) of H&E stained 10 mm frozen sections taken from mdx gastrocnemius muscles 5 days post NTX-injury. Groups
were treated with vehicle, THI, STAT3 inhibitor WP1066, or THI+WP1066. F) Quantification of regenerating myofibers/mm
2 (n=3/group). Scale
bar=50 microns. G) Analysis of SCs by flow cytometry as described in Figure 5F. Data are means 6 SD, n=5/group, * indicates p#0.05.
doi:10.1371/journal.pone.0037218.g007
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37218Anti-integrin alpha-7 APC was from R&D Systems (Minneapolis,
MN, USA). Rho A inhibitor (H-1152), S1P and S1PR antagonist
(BML-241, W123) were obtained from Cayman Chemical (Ann
Arbor, MI, USA). S1PR2 antagonist, JTE-013 was obtained from
Tocris Biosciences (Ellsville, MO, USA). STAT3 inhibitor,
WP1066 and Rac1 inhibitor 1 were obtained from EMD
Biosciences (Gibbstown, NJ, USA). NTX, Ponceau S, protease
inhibitors, collagenase Type IIA and dispase were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Enhanced chemilumines-
cence (ECL) was from Amersham Bioscience (Piscataway, NJ,
USA). SYBR-Green PCR master mix and reverse transcription kit
were purchased from Applied Biosciences (Foster City, CA, USA).
PCR primers were from Integrated DNA Technology (San Diego,
CA, USA). DMEM, Ham’s F-10, 20% FBS and horse serum were
from Mediatech (Manassas, VA, USA). Penicillin-streptomycin
was from Invitrogen (Carlsbad, CA, USA). FGF was from
Millipore (Billerica, MA, USA). Opti-MEM was purchased from
UCSF Cell Culture Facility (San Francisco, CA, USA). Recom-
binant mouse Il-6 (R&D systems, Minneapolis, MN, USA).
Animal Subjects
Mice were housed under specific pathogen-free conditions. The
animal protocol used in these experiments was approved by the
Institutional Animal Care and Use Committee of the Children’s
Hospital Oakland Research Institute, and is in accordance with
the National Institutes of Health guidelines for use of live animals.
C57BL/6, C57BL10/J and mdx mice (C57BL/10ScSn-
Dmdmdx/J) were obtained from Jackson Laboratories (Bar
Harbor, ME, USA). Sphk1 KO mice [36] were described
previously. SPL gene-trap KO and reporter mice [74] were from
Philippe Soriano (Mount Sinai School of Medicine, NY, USA).
Age- (2–3 months) and gender-matched controls were used in all
procedures.
Microarray Studies and Data Analysis
Analysis of temporal changes in S1P-related gene expression
during the course of gastrocnemius muscle regeneration after
NTX injury of WT mice was performed as described previously
[32]. All subsequent studies using NTX injury were modified to
avoid skin incision.
Focal Muscle Injury and Isolation
Focal muscle injury and analysis of muscle regeneration in vivo
was performed using single NTX injection (20 microliters) into
tibialis anterior and gastrocnemius muscles. Direct intramuscular
injection with NTX dissolved at 10 mg/mL in sterile PBS was
used. Mice were euthanized by CO2 inhalation and cervical
dislocation 6 hours to 20 days post-injury. Whole muscle
(uninjured and regenerating) was isolated and prepared for (1)
qRT-PCR, (2) immunoblotting, (3) muscle S1P measurement, (4)
and flow cytometry. Plasma was also collected for S1P measure-
ment and tissue was also used for cryosectioning and histology
(described below).
Real-Time Quantitative RT-PCR
For qRT-PCR studies, cDNA was generated from 1 mg RNA
using a reverse transcription kit. Real-time PCR reaction was
carried out on an ABI 7900HT thermocycler (Applied Biosystems,
Carlsbad, CA, USA) coupled with SYBR Green technology using
gene specific primers (shown below) and cDNA reaction mixture.
All results shown represent gene expression that has been
normalized to GAPDH levels.
Primer Sequences
Sphk1
Forward Primer CGTGGACCTCGAGAGTGAGAA
Reverse Primer AGGCTTGCTAGGCGAAAGAAG
Sphk2
Forward Primer GCTTTCACCCATCGCTGAAG
Reverse Primer GGCAGGAACCCCGAAGAT
Sgpl1
Forward Primer GTTGGGCCGCCTTGATG
Reverse Primer GATGATCTGTTTGGTAGCTTCAACA
Sgpp1
Forward Primer CCCATTGGTGGACCTGATTG
Reverse Primer GATGAGCGGCGCATATTTG
s1pr1
Forward Primer ACCTAGCCCTCTCGGACCTATT
Reverse Primer CCCAGACAACAGCAGGTTAGC
s1pr2
Primer GCCATCGCCATCGAGAGA
Reverse Primer TGTCACTGCCGTAGAGCTTGA
s1pr3
Forward Primer GCCAGTCTTGGGAAATGACACT
Reverse Primer TGCCAGTTTCCCCACGTAA
s1pr4
Forward Primer CTGCCCGCCGCAAGT
Reverse Primer CACAAAGGCCACCAAGATCA
s1pr5
Forward Primer TGGCTGTGTGTGCCTTCATT
Reverse Primer GCGGACCAGCACCAAGAG
Cdh15 (M-cadherin)
Forward Primer CCTGATGGGCAGTTCAAGATC
Reverse Primer CACGGACAGCACACCTTCAT
Pax-7
Forward Primer AAAAAACCCTTTCCCTTCCTACA
Reverse Primer AGCATGGGTAGATGGCACACT
Met (c-Met)
Forward Primer CAGCATCGCTCAAATTCAGAGA
Reverse Primer GGCCCAGCTGTTTCAGTGA
Gapdh
Forward Primer CCAGCCTCGTCCCGTAGA
Reverse Primer CGCCCAATACGGCCAAA
Immunoblotting
Frozen muscles were homogenized in lysis buffer supplemented
with protease inhibitors. Sodium orthovanadate and sodium
fluoride (1 and 10 mM final concentrations, respectively) were
also added to the lysates to inhibit phosphatase activity. Proteins
were separated by SDS-PAGE and transferred by electroblotting
to nitrocellulose membranes. Equivalent loading and transfer of
proteins were verified by staining the blots with Ponceau S.
Immunoblotting was performed using standard SDS-PAGE
Western blotting as previously described in our laboratory [75].
Immunoreactive bands were detected by enhanced chemilumi-
nescence and quantified by densitometric analysis of digitized
autoradiograms with NIH Image 1.61 software.
S1P Quantification
For S1P measurements, mouse muscle was homogenized in
0.5 ml of methanol using a glass homogenizer and a tip sonicator.
Following homogenization, 1.0 ml of chloroform/methanol 1:1
was added and the sample was incubated over night at 48uC.
Sample was dried down and resuspended in 3 ml of chloroform/
methanol 2:1, and the extract was made basic by adding 50 mlo f
1 M KOH in methanol. A two-phase separation was obtained by
adding 0.5 ml of water. The aqueous phase was recovered and
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two-phase separation was obtained by adding 1 ml of chloroform/
methanol 2:1 and the organic phase was recovered. S1P was
extracted from 10 ml of mouse plasma by adding 0.4 ml of
methanol followed by vortexing and incubation for 30 minutes at
30uC. The sample was spun in a tabletop centrifuge at 14,000 g
and the supernatant was recovered. 17C-S1P was used as an
internal standard. Lipids were separated on a C18 column
(2.1650 mm; Kinetex) (Phenomenex, Torrance, CA, USA) at a
flow rate of 0.25 ml/min. The gradient used was from 45% to
99% methanol containing 1% acetic acid and 5 mM ammonium
acetate. The data were acquired in positive mode on a Micromass
Quattro LCZ MS (Waters Corp., Milford, MA, USA). Lipids were
identified based on their specific precursor and product ion pair
and quantitated using multiple reaction monitoring as described
[76].
SC Quantification by Flow Cytometry
The gastrocnemius muscles harvested after focal NTX injury
were subjected to enzymatic dissociation for 2 hours. The cell
suspension was filtered through a 70 mm cell strainer, followed by
centrifugation and washing. One million cells were counted and
incubated with fluorescently conjugated monoclonal antibodies for
anti-CD31, anti-CD34, anti-CD45, anti-Sca-1 anti-integrin alpha-
7 on ice for 45 minutes in the dark, followed by washing and
centrifugation. Antibody/fluorophore combinations used were:
anti-CD31 PE-Cy7, anti-CD34 efluor 450, anti-CD45 FITC, anti-
Sca-1 PerCP Cy5-5, anti-integrin alpha-7 APC. Positive events
and gates were determined by comparing fluorophore signal
intensities between the unstained control and each single
antibody/fluorophore control. Appropriate isotype controls were
used. SCs were identified using CD45-, CD31-, Sca-1-, CD34+
and integrin alpha-7+ markers. Data were acquired with the BD
LSRFortessa flow cytometer, and in each sample 100,000 events
were recorded. Subsequent analysis and flow cytometry plots were
generated using FlowJo v.7.2.5 (TreeStar, Inc., Ashland, OR,
USA).
Bulk Activation of Myofiber-Associated SCs
Most of the procedures involving SCs were performed as
previously described [77,78]. Tibialis anterior and gastrocnemius
hindlimb muscles were injected with NTX through the skin with
two to five injury sites made for each muscle (0.1 mg NTX
delivered per site of injury), and muscles were harvested at various
assay-dependent time points. SCs were then isolated from
harvested muscle for in vitro assays.
SC Isolation and SC Derived Myoblast Culture
SCs were isolated as described previously [77]. Briefly, whole
muscle was initially digested at 37uC in DMEM, penicillin
(100 U/ml)–streptomycin (100 mg/ml), and 300 U/ml Collage-
nase Type IIA. SC-associated myofibers then underwent several
trituration, sedimentation and washing procedures before contin-
ued enzymatic digestion with 4 U/ml Collagenase Type IIA and
10 U/ml Dispase. Myogenic purity was confirmed by the
generation of proliferating, fusion-competent myoblasts after
24 hours in growth medium (Ham’s F-10 plus 20% FBS and
5 ng/ml bFGF), and de novo myotube formation after 48–
72 hours in differentiation medium (DMEM +2% horse serum,
penicillin-streptomycin) [79]. For cell culture and analysis, injury-
activated or uninjured SCs were cultured on 1:500 ECM/PBS-
coated chamber slides (Nunc, Rochester, NY, USA). To assess the
in vitro efficiency of myogenic repair, cells were cultured in Opti-
MEM in the presence of specified sera for 24 hours (to examine
proliferating myogenesis), or switched to differentiation medium
for an additional 48–72 hours (to examine fusion competence). In
some experiments, specific S1PR antagonists were added to
culture (see Reagents for details). All transfections except siRNA
(see below) were performed by Ca2PO4 precipitation method.
Twenty-four hours later, the transfection mix was replaced with
normal media (Ham’s-F10 plus 20% FBS, and 5 ng/ml bFGF). All
treatments were initiated 24 hours after the media change.
Other Cell Culture Conditions
Pooled human umbilical vein endothelial cells (Lonza Inc,
Allendale, NJ, USA) Lot # 0000115425 Cat# C2519A were
propagated in Endothelial cell medium bullet kit-2 (Lonza Inc,
Allendale, NJ, USA). C3H/10T1/2 Clone 8 pericytes Embryonic-
Lot# 58613480 (ATCC, Manassas, VA, USA) were propagated in
Eagle’s Basal Medium with 2 mM L-glutamine, 1.5 g/L sodium
bicarbonate and Earle’s BSS (University of California San
Francisco Cell Culture Facility, San Francisco, CA, USA) with
10% heat inactivated FBS (Invitrogen, Grand Island, NY, USA).
M25.2 mesoangioblast cells were maintained in Iscove’s medium
supplemented with 10% FBS, 0.1 U/ml penicillin, 0.1 mg/ml
streptomycin, 2.0 mM L-glut, 0.1 mM nonessential amino acids
and minimal essential medium vitamin solution (Gibco, Carlsbad,
CA, USA) and 10 ng/ml purified LIF (Chemicon International,
Temecula, CA, USA).
Histological Procedures
Most histological procedures were performed as previously
described [77]. For in vitro studies, 10 mM BrdU was added for
2 hours prior to cell fixation (performed in 70% ethanol/PBS) and
subsequent immunoassays. BrdU-specific immunostaining re-
quired nuclear permeabilization with treatment of 4N HCl.
Following cell permeabilization in PBS containing 1% FBS and
+0.25% Triton X-100, primary antibodies were incubated
overnight at 4uC and followed by multiple washes in PBS
containing 1% FBS. Fluorophore-conjugated, species-specific
secondary antibodies (diluted 1:500 in PBS containing 1% FBS)
were added for 1–2 hours at room temperature. For histological
assays, dissected muscle was treated in a 25% sucrose/PBS
solution, embedded in OCT compound (Tissue Tek, Torrance,
CA, USA) and frozen in liquid nitrogen-cooled isopentane. Ten-
micron thick cryosections were cut using a Tissue-Tek Cryo3
Cryostat from Sakura (Torrance, CA, USA). Pax7 and M-
cadherin SC quantification were performed as follows:
Tibialis anterior muscles received single, focal injury injections
of NTX to muscle belly centers. At 10 days following injury,
animals were euthanized (isoflurane), and injured/uninjured
control muscles were harvested. Isolated muscles were incubated
in ice-cold 25% sucrose/PBS solution for approximately 4 hours
until sedimentation, followed by freezing in OCT compound.
Cryosections (10 mm) were performed at 200 mm increments
throughout the entire muscle, including the whole volume of
injured tissue. Serial sections were then examined by hematoxylin
and eosin staining to determine the site of injury ‘‘epicenters’’.
These sections were subsequently used for immunostaining and
analysis of Pax7 and M-cadherin SC populations. SCs were
initially identified based on localization of nuclear staining
(Hoechst) within sub-laminar positions. Cell identity was then
confirmed by Pax7 or M-cadherin expression. Total numbers were
determined from multiple epicenter sections of individually-
injured muscles, and based on quantifications performed within
normalized surface areas for all samples analyzed. Data shown for
Figure 2E depicts the increase in SCs, at post-injury day 10,
relative to basal state muscles (D0=uninjured).
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Muscle sections were air-dried, fixed in 4% paraformaldehyde
and washed in PBS containing 0.01% Tween 20 (PBST). Sections
were blocked with PBST containing 5% goat serum and 0.3%
Triton X-100. After washing, sections were incubated with anti-
Pax7 and anti-laminin antibodies, respectively, followed by
incubation with secondary Alexa fluor 488 goat anti-mouse IgG
and Alexa Fluor 546 goat anti-rabbit IgG in PBST containing 5%
goat serum. Sections were then counterstained with Hoechst after
washing and mounted in Vectashield mounting medium (Vector
Labs, Burlingame, CA, USA). Fluorescence was observed with a
Carl Zeiss Axioskop 50 fluorescent microscope, and images were
captured using Nikon DS-Ri1 camera.
Inhibitor Studies In Vivo
JTE-013 was administered by subcutaneous injection at a
dosage of 1 mg/kg daily starting 1 day prior to muscle injury.
WP1066, which was dissolved in a 20:80 mixture of DMSO:PEG,
was injected intraperitoneally at a dose of 20 mg/kg daily starting
1 day prior to injury. For THI treatment, animals were injured
with a single NTX injection as described above and were given
50 mg/L THI in drinking water containing glucose ad libitum
from 2 to 5 days after injury (muscle S1P study), or from 21t o5
days after injury (mdx study). The control group received glucose
water only. Animals were sacrificed 5 days post injury, and tissues
were collected.
S1PR2 Knockdown by siRNA
SC-derived primary myoblasts were plated in six-well plates in
Ham’s F10 medium containing 20% FBS and 5 ng/ml FGF. After
24 h, 50 nM S1PR2 siRNA smartpools (Dharmacon, Lafayette,
CO, USA) were transfected with Dharmafect 1 (Dharmacon,
Lafayette, CO, USA). Control cells were similarly treated with
transfection reagent only. Twenty-four hours later, the transfection
mix was replaced with Ham’s-F10 plus 20% FBS, and 5 ng/ml
bFGF. Forty-eight hours after transfection, the cells were
evaluated for S1PR2 mRNA expression and phospho-STAT3
protein levels.
Rac1 GTPase Activation Assay
Rac1 activation assays were performed as described previously
[80]. Briefly, myoblasts were grown in 100 mm culture plates to
80% confluency. Cells were treated with S1PR2 antagonist JTE-
013 for 6 hours. After washing, cells were lysed in cold lysis buffer
containing 20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% Triton X-
100, 10 mM MgCl2, 0.2 mM phenylmethyl sulfonyl fluoride and
protease inhibitor cocktail. Cell lysate was cleared by centrifuga-
tion at 12,000 g for 10 minutes, and cell lysate was incubated with
GST-Pak1 agarose beads for 1 hour. After washing, samples were
separated on 12% SDS-PAGE. Activated Rac1 was detected by
immunoblotting using Rac1 monoclonal antibody.
Plasmid Constructs
Plasmid encoding human SphK1 (pBabe-GFP-SK1) was
described previously [34]. Plasmid encoding enhanced green
fluorescent protein (GFP), pcDNA3-EGFP (Addgene plasmid
13031), dominant negative Rac1 pRK5-myc-Rac1-T17N (Ad-
dgene plasmid 12984) and WT Rho A construct pRK5-myc-
RhoA-WT (Addgene plasmid 12962) were purchased from
Addgene (Cambridge, MA, USA) and kindly provided by Douglas
Golenbock (University of Massachusetts), Gary Bokoch (Scripps
Research Institute), and Alan Hall (Memorial Sloan Kettering
Institute), respectively.
Statistical Analysis
Values are expressed as means 6 SD. Student’s unpaired t-test
was used to compare two data sets. Comparisons among three
groups were tested by one-way ANOVA using Prism GraphPad
version 3.02 (GraphPad Software, San Diego, CA, USA). When
the P value obtained from ANOVA was significant, Tukey’s test
was applied to test for differences among groups. Significance was
considered to be P,0.05.
Supporting Information
Figure S1 STAT3 activation in myoblasts and vascular
cells treated with S1P ± S1PR2 inhibitor. SC-derived
myoblasts, HUVECs, C3H/10T1/2 cells and M25.2 cells were
starved overnight in serum-free media. After starvation, a subset of
cells were pre-treated with 10 mM JTE-013 for 30 minutes. Cells
were then treated with 1 mM S1P dispersed in PBS with 4 mg/ml
of fatty acid free BSA with or without the addition of 10 mM JTE-
013 for an additional 30 minutes. Control cells received an equal
concentration of BSA in serum-free media. Cells were lysed in the
presence of protease and phosphatase inhibitors and immuno-
blotted. A) Immunoblotting of whole cell lysates show relative
levels of phosphorylated STAT3 (STAT3-P), total STAT3
(STAT3-T) and actin. B) STAT3-P/STAT3-T ratio determined
by densitometry quantification using ImageJ software. BSA
control is arbitrarily set at 1, except for C3H/10T1/2 cells in
which STAT3-P was undetectable.
(TIFF)
Acknowledgments
We would like to acknowledge Nelle Cronen for expert administrative
assistance and Max Soghikian for technical support of immunoblotting
studies. We dedicate this study to Dr. William Fishbein for his inspiration
and guidance.
Author Contributions
Conceived and designed the experiments: JDS KCL WIL MEC BO AK.
Performed the experiments: KCL WIL MEC MZ HF EPH BO. Analyzed
the data: EPH RLP JDS WIL KCL MEC HF BO AK. Contributed
reagents/materials/analysis tools: RLP EPH. Wrote the paper: JDS.
References
1. Deconinck N, Dan B (2007) Pathophysiology of duchenne muscular dystrophy:
current hypotheses. Pediatr Neurol 36: 1–7.
2. Hoffman EP, Brown RH, Jr., Kunkel LM (1987) Dystrophin: the protein
product of the Duchenne muscular dystrophy locus. Cell 51: 919–928.
3. Heslop L, Morgan JE, Partridge TA (2000) Evidence for a myogenic stem cell
that is exhausted in dystrophic muscle. J Cell Sci 113 (Pt 12): 2299–2308.
4. Le Grand F, Rudnicki MA (2007) Skeletal muscle satellite cells and adult
myogenesis. Curr Opin Cell Biol 19: 628–633.
5. Kastner S, Elias MC, Rivera AJ, Yablonka-Reuveni Z (2000) Gene expression
patterns of the fibroblast growth factors and their receptors during myogenesis of
rat satellite cells. J Histochem Cytochem 48: 1079–1096.
6. Zammit PS, Partridge TA, Yablonka-Reuveni Z (2006) The skeletal muscle
satellite cell: the stem cell that came in from the cold. J Histochem Cytochem 54:
1177–1191.
7. Mozzetta C, Minetti G, Puri PL (2009) Regenerative pharmacology in the
treatment of genetic diseases: the paradigm of muscular dystrophy. Int J Biochem
Cell Biol 41: 701–710.
8. Maceyka M, Milstien S, Spiegel S (2008) Sphingosine-1-phosphate: the Swiss
army knife of sphingolipid signaling. J Lipid Res 50: S272–S276.
9. Young N, Van Brocklyn JR (2006) Signal transduction of sphingosine-1-
phosphate G protein-coupled receptors. ScientificWorldJournal 6: 946–966.
10. Spiegel S, Milstien S (2006) Functions of the multifaceted family of sphingosine
kinases and some close relatives. J Biol Chem 282: 2125–2129.
S1P Facilitates Muscle Repair through S1PR2/STAT3
PLoS ONE | www.plosone.org 14 May 2012 | Volume 7 | Issue 5 | e3721811. Serra M, Saba JD (2010) Sphingosine 1-phosphate lyase, a key regulator of
sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 50:
349–362.
12. Nosi D, Vassalli M, Polidori L, Giannini R, Tani A, et al. (2004) Effects of S1P
on myoblastic cell contraction: possible involvement of Ca-independent
mechanisms. Cells Tissues Organs 178: 129–138.
13. Formigli L, Meacci E, Sassoli C, Squecco R, Nosi D, et al. (2007) Cytoskeleton/
stretch-activated ion channel interaction regulates myogenic differentiation of
skeletal myoblasts. J Cell Physiol 211: 296–306.
14. Sbrana F, Sassoli C, Meacci E, Nosi D, Squecco R, et al. (2008) Role for stress
fiber contraction in surface tension development and stretch-activated channel
regulation in C2C12 myoblasts. Am J Physiol Cell Physiol 295: C160–172.
15. Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, et al. (2009) Sphingosine
1-phosphate increases glucose uptake through trans-activation of insulin
receptor. Cell Mol Life Sci 66: 3207–3218.
16. Cencetti F, Bernacchioni C, Nincheri P, Donati C, Bruni P (2010) Transforming
growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts
via up-regulation of sphingosine kinase-1/S1P3 axis. Mol Biol Cell 21:
1111–1124.
17. Baranowski M, Charmas M, Dlugolecka B, Gorski J (2011) Exercise increases
plasma levels of sphingoid base-1 phosphates in humans. Acta Physiol (Oxf) 203:
373–380.
18. Meacci E, Bini F, Sassoli C, Martinesi M, Squecco R, et al. (2010) Functional
interaction between TRPC1 channel and connexin-43 protein: a novel pathway
underlying S1P action on skeletal myogenesis. Cell Mol Life Sci 67: 4269–4285.
19. Formigli L, Sassoli C, Squecco R, Bini F, Martinesi M, et al. (2009) Regulation
of transient receptor potential canonical channel 1 (TRPC1) by sphingosine 1-
phosphate in C2C12 myoblasts and its relevance for a role of mechanotransduc-
tion in skeletal muscle differentiation. J Cell Sci 122: 1322–1333.
20. Danieli-Betto D, Peron S, Germinario E, Zanin M, Sorci G, et al. (2010)
Sphingosine 1-phosphate signaling is involved in skeletal muscle regeneration.
Am J Physiol Cell Physiol 298: C550–558.
21. Sassoli C, Formigli L, Bini F, Tani A, Squecco R, et al. (2011) Effects of S1P on
skeletal muscle repair/regeneration during eccentric contraction. Journal of
Cellular and Molecular Medicine 15: 2498–2511.
22. Sabbadini RA, Danieli-Betto D, Betto R (1999) The role of sphingolipids in the
control of skeletal muscle function: a review. Ital J Neurol Sci 20: 423–430.
23. Zanin M, Germinario E, Dalla Libera L, Sandona D, Sabbadini RA, et al.
(2008) Trophic action of sphingosine 1-phosphate in denervated rat soleus
muscle. Am J Physiol Cell Physiol 294: C36–46.
24. Nincheri P, Bernacchioni C, Cencetti F, Donati C, Bruni P (2010) Sphingosine
kinase-1/S1P1 signalling axis negatively regulates mitogenic response elicited by
PDGF in mouse myoblasts. Cell Signal 22: 1688–1699.
25. Bruni P, Donati C (2008) Pleiotropic effects of sphingolipids in skeletal muscle.
Cell Mol Life Sci 65: 3725–3736.
26. Nagata Y, Partridge T, Matsuda R, Zammit P (2006) Entry of muscle satellite
cells into the cell cycle requires sphingolipid signaling. J Cell Biol 174: 245–253.
27. Herr DR, Fyrst H, Phan V, Heinecke K, Georges R, et al. (2003) Sply regulation
of sphingolipid signaling molecules is essential for Drosophila development.
Development 130: 2443–2453.
28. Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-
STAT. Science 296: 1653–1655.
29. McKay BR, De Lisio M, Johnston AP, O’Reilly CE, Phillips SM, et al. (2009)
Association of interleukin-6 signalling with the muscle stem cell response
following muscle-lengthening contractions in humans. PLoS One 4: e6027.
30. Toth KG, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, et al. (2011) IL-6
induced STAT3 signalling is associated with the proliferation of human muscle
satellite cells following acute muscle damage. PLoS One 6: e17392.
31. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW (2009)
Immune-mediated mechanisms potentially regulate the disease time-course of
duchenne muscular dystrophy and provide targets for therapeutic intervention.
PM R 1: 755–768.
32. Zhao P, Iezzi S, Carver E, Dressman D, Gridley T, et al. (2002) Slug is a novel
downstream target of MyoD. Temporal profiling in muscle regeneration. J Biol
Chem 277: 30091–30101.
33. Bandhuvula P, Honbo N, Wang GY, Jin ZQ, Fyrst H, et al. (2011) S1P lyase: a
novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol
Heart Circ Physiol 300: H1753–1761.
34. Kumar A, Oskouian B, Fyrst H, Zhang M, Paris F, et al. (2011) S1P lyase
regulates DNA damage responses through a novel sphingolipid feedback
mechanism. Cell Death Dis 2: e119.
35. Vessey DA, Kelley M, Li L, Huang Y, Zhou HZ, et al. (2006) Role of
sphingosine kinase activity in protection of heart against ischemia reperfusion
injury. Med Sci Monit 12: BR318–324.
36. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, et al. (2004) Mice deficient in
sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279:
52487–52492.
37. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked
muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81:
1189–1192.
38. Schwab S, Pereira J, Matloubian M, Xu Y, Huang Y, et al. (2005) Lymphocyte
sequestration through S1P lyase inhibition an disruption of S1P gradients.
Science 309: 1735–1739.
39. Ieronimakis N, Balasundaram G, Rainey S, Srirangam K, Yablonka-Reuveni Z,
et al. (2010) Absence of CD34 on murine skeletal muscle satellite cells marks a
reversible state of activation during acute injury. PLoS One 5: e10920.
40. Rapizzi E, Donati C, Cencetti F, Nincheri P, Bruni P (2008) Sphingosine 1-
phosphate differentially regulates proliferation of C2C12 reserve cells and
myoblasts. Mol Cell Biochem 314: 193–199.
41. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, et al. (1998) STAT3
orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle
transition. EMBO J 17: 6670–6677.
42. Spangenburg EE, Booth FW (2002) Multiple signaling pathways mediate LIF-
induced skeletal muscle satellite cell proliferation. Am J Physiol Cell Physiol 283:
C204–211.
43. Kami K, Senba E (2002) In vivo activation of STAT3 signaling in satellite cells
and myofibers in regenerating rat skeletal muscles. J Histochem Cytochem 50:
1579–1589.
44. Wang K, Wang C, Xiao F, Wang H, Wu Z (2008) JAK2/STAT2/STAT3 are
required for myogenic differentiation. J Biol Chem 283: 34029–34036.
45. Trenerry MK, Della Gatta PA, Cameron-Smith D (2011) JAK/STAT signaling
and human in vitro myogenesis. BMC Physiol 11: 6.
46. Lee H, Deng J, Kujawski M, Yang C, Liu Y, et al. (2010) STAT3-induced
S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med
16: 1421–1428.
47. Pinney DF, Emerson CP, Jr. (1989) 10T1/2 cells: an in vitro model for molecular
genetic analysis of mesodermal determination and differentiation. Environ
Health Perspect 80: 221–227.
48. Mounier R, Chretien F, Chazaud B (2011) Blood vessels and the satellite cell
niche. Curr Top Dev Biol 96: 121–138.
49. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, et al. (2002)
The meso-angioblast: a multipotent, self-renewing cell that originates from the
dorsal aorta and differentiates into most mesodermal tissues. Development 129:
2773–2783.
50. Berry SE, Liu J, Chaney EJ, Kaufman SJ (2007) Multipotential mesoangioblast
stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular
dystrophy. Regen Med 2: 275–288.
51. Kuroki M, O’Flaherty JT (1999) Extracellular signal-regulated protein kinase
(ERK)-dependent and ERK-independent pathways target STAT3 on serine-727
in human neutrophils stimulated by chemotactic factors and cytokines.
Biochem J 341 (Pt 3): 691–696.
52. Chung J, Uchida E, Grammer TC, Blenis J (1997) STAT3 serine
phosphorylation by ERK-dependent and -independent pathways negatively
modulates its tyrosine phosphorylation. Mol Cell Biol 17: 6508–6516.
53. Raptis L, Arulanandam R, Geletu M, Turkson J (2011) The R(h)oads to Stat3:
Stat3 activation by the Rho GTPases. Exp Cell Res 317: 1787–1795.
54. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, et al. (2000)
Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290:
144–147.
55. Porter J, Khanna S, Kaminski H, Rao J, Merriam A, et al. (2002) A chronic
inflammatory response dominates the skeletal muscle molecular signature in
dystrophin-deficient mdx mice. Hum Mol Genet 11: 263–272.
56. Aguilar A, Saba JD (2012) Truth and consequences of sphingosine-1-phosphate
lyase. Adv Enzyme Regul 52: 17–30.
57. Zhao Y, Gorshkova IA, Berdyshev E, He D, Fu P, et al. (2011) Protection of
LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase
suppression. Am J Respir Cell Mol Biol 45: 426–435.
58. Bagdanoff JT, Donoviel MS, Nouraldeen A, Carlsen M, Jessop TC, et al. (2010)
Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid
arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imida-
zol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imi-
dazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem 53: 8650–8662.
59. Frias MA, James RW, Gerber-Wicht C, Lang U (2009) Native and reconstituted
HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of
sphingosine-1-phosphate. Cardiovasc Res 82: 313–323.
60. Sekine Y, Suzuki K, Remaley AT (2011) HDL and sphingosine-1-phosphate
activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors,
and promote cell migration and invasion. Prostate 71: 690–699.
61. Dogra C, Srivastava DS, Kumar A (2008) Protein-DNA array-based
identification of transcription factor activities differentially regulated in skeletal
muscle of normal and dystrophin-deficient mdx mice. Mol Cell Biochem 312:
17–24.
62. White JD, Bower JJ, Kurek JB, Austin L (2001) Leukemia inhibitory factor
enhances regeneration in skeletal muscles after myoblast transplantation. Muscle
Nerve 24: 695–697.
63. Childs TE, Spangenburg EE, Vyas DR, Booth FW (2003) Temporal alterations
in protein signaling cascades during recovery from muscle atrophy. Am J Physiol
Cell Physiol 285: C391–398.
64. Spangenburg EE, Booth FW (2006) Leukemia inhibitory factor restores the
hypertrophic response to increased loading in the LIF(2/2) mouse. Cytokine
34: 125–130.
65. Skoura A, Hla T (2009) Regulation of vascular physiology and pathology by the
S1P2 receptor subtype. Cardiovasc Res 82: 221–228.
66. Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, et al. (2010) S1P(2), the
G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates
tumor angiogenesis and tumor growth in vivo in mice. Cancer Res 70: 772–781.
S1P Facilitates Muscle Repair through S1PR2/STAT3
PLoS ONE | www.plosone.org 15 May 2012 | Volume 7 | Issue 5 | e3721867. Medlin MD, Staus DP, Dubash AD, Taylor JM, Mack CP (2010) Sphingosine 1-
phosphate receptor 2 signals through leukemia-associated RhoGEF (LARG), to
promote smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 30:
1779–1786.
68. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, et al. (2003)
Ligand-dependent inhibition of B16 melanoma cell migration and invasion via
endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of
cellular RAC activity. J Biol Chem 278: 32841–32851.
69. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P (2008)
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle
hypertrophy. Cell Metab 7: 33–44.
70. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, et al. (2009)
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
Science 325: 1254–1257.
71. Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, et al. (2009)
Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune
system function yet prevents early lethality and non-lymphoid lesions. PLoS One
4: e4112.
72. Yu XQ, Kramer J, Moran L, O’Neill E, Nouraldeen A, et al. (2010)
Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybu-
tyl imidazole-induced peripheral lymphocyte sequestration through increasing
lymphoid sphingosine 1-phosphate. Xenobiotica 40: 350–356.
73. Oskouian B, Mendel J, Shocron E, Lee MA, Jr., Fyrst H, et al. (2005)
Regulation of sphingosine-1-phosphate lyase gene expression by members of the
GATA family of transcription factors. J Biol Chem 280: 18403–18410.
74. Schmahl J, Raymond CS, Soriano P (2007) PDGF signaling specificity is
mediated through multiple immediate early genes. Nat Genet 39: 52–60.
75. Oskouian B, Sooriyakumaran P, Borowsky A, Crans A, Dillard-Telm L, et al.
(2006) Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-
dependent pathways and is downregulated in colon cancer. Proc Natl Acad
Sci U S A 103: 17384–17389.
76. Sullards MC, Merrill AHJ (2001) Analysis of sphingosine-1-phosphate,
ceramides, and other bioactive sphingolipids by high-performance liquid
chromatography. Science’s STKE 67: 1–11.
77. Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and
Notch induces CDK inhibitors in old muscle stem cells. Nature 454: 528–532.
78. Carlson ME, Conboy IM (2007) Loss of stem cell regenerative capacity within
aged niches. Aging Cell 6: 371–382.
79. Morgan JE, Partridge TA (2003) Muscle satellite cells. Int J Biochem Cell Biol
35: 1151–1156.
80. Pellegrin S, Mellor H (2008) Rho GTPase activation assays. Curr Protoc Cell
Biol Chapter 14: Unit 14 18.
S1P Facilitates Muscle Repair through S1PR2/STAT3
PLoS ONE | www.plosone.org 16 May 2012 | Volume 7 | Issue 5 | e37218